Emanuele Zucca

Also affiliated with Institute of Oncology Research, Università della Svizzera italiana

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 13 papers. Top paper: “Toward New Treatments for Mantle-Cell Lymphoma?”.

Toward New Treatments for Mantle-Cell Lymphoma?

New England Journal of Medicine(2013)10.1056/nejme1307596

N/A

1.3DataRank · unranked

20 citations

Francesco Bertoni, Emanuele Zucca

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00396-6

N/A

0.903DataRank · unranked

34 citations

Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani +19 more

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

Blood Advances(2021)10.1182/bloodadvances.2021004467

N/A

0.659DataRank · unranked

80 citations

C. N. Burggraaff, M. W. Heymans, U. Dührsen, Andreas Hüttmann, C. Schmitz +20 more

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0068

N/A

0.531DataRank · unranked

17 citations

Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas +19 more

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Haematologica(2022)10.3324/haematol.2021.279957

N/A

0.515DataRank · unranked

30 citations

Sara Napoli, Luciano Cascione, Giulio Sartori, Laura Barnabei, Eugenio Gaudio +20 more

Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

American Journal of Hematology(2022)10.1002/ajh.26715

N/A

0.494DataRank · unranked

26 citations

Isildinha M. Reis, Thomas M. Habermann, Brian K. Link, Catherine Thiéblemont, Annarita Conconi +7 more

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)

eClinicalMedicine(2023)10.1016/j.eclinm.2023.102221

N/A

0.385DataRank · unranked

12 citations

Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini +19 more

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.11.14.566994

N/A

0.241DataRank · unranked

4 citations

Eugenio Gaudio, Sara Napoli, Charles Herbaux, Chiara Tarantelli, Roberta Bordone +15 more

SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY

Hematological Oncology(2023)10.1002/hon.3163_80

N/A

0DataRank · unranked

3 citations

Maria Cristina Pirosa, Sämi Schär, Marianne Brodtkorb, Björn E. Wahlin, Micaela Hernberg +19 more

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Blood Advances(2024)10.1182/bloodadvances.2023012291

N/A

0DataRank · unranked

8 citations

Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas, Chiara Tarantelli +16 more

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.01.522017

N/A

0DataRank · unranked

2 citations

Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas +19 more

CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL

Hematological Oncology(2023)10.1002/hon.3163_15

N/A

0DataRank · unranked

6 citations

Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer +45 more